ArrowBack to Principal
News

Maxion Therapeutics Highly Commended in ‘Employer of the Year’ Category at Cambridge Independent Science and Technology Awards

Cambridge, UK
·
June 6, 2024
News

Maxion Therapeutics is pleased to announce it has been recognised as ‘Highly Commended’ in the ‘Employer of the Year’ category at the Cambridge Independent Science and Technology Awards 2024. The category recognises organisations in any field of science and technology that are attractive places to work, with a commitment to its team, corporate responsibility and the green agenda – truly supporting its employees and community.

Director of Operations Sylwia Mankowska attended the ceremony on 16th May at Hinxton Hall, Wellcome Genome Campus, Cambridgeshire with a group of representatives (Mark Bushell, Director of Technology, Pedro Villar, Associate Principal Scientist, and Edward Humphries, Principal Scientist).


She commented:

It is with great pleasure that I, on behalf of the Board, welcome Arndt to Maxion. As we are expanding our portfolio of KnotBodies and driving our lead programme towards the clinic, his leadership and drug development expertise will be invaluable. I look forward to working with Arndt to shape the vision and drive the Company forward.

Dr. Arndt Schottellius, CEO, said:

We are delighted to be Highly Commended at this year’s Cambridge Independent Science and Technology Awards in the ‘Employer of the Year’ category”

Dr Arndt Schottelius said: “At Maxion, we are actively pursuing world-class science, with a strong entrepreneurial spirit that runs through the entire organisation - no matter the role. Since joining Maxion in March, I’ve be impressed by how our senior leadership enables and empowers the team to achieve its goals with close alignment. This is especially fundamental as we work towards changing the therapeutic landscape for autoimmune and chronic pain patients worldwide, progressing best-in-class and first-in-class candidates, based upon our Knotbody® technology, ever closer towards the clinic.”

Last year, Maxion grew its team from 8 to 28 people following its pre-Series A fundraise - successfully attracting talent from around the world with a 50/50 gender split and sponsoring two Global Talent Visas. The company is also committed to nurturing future talent through its student placement programme.

Maxion’s scientists, from junior through to senior roles, are regularly given the opportunity to present and participate in international conferences, providing valuable exposure and networking opportunities. Its flexible working arrangements and enhanced maternity and paternity leave policies enable employees to achieve a healthy work-life balance.

The company is also deeply committed to corporate social responsibility and the green agenda. It actively participates in the Green Impact Scheme, an award-winning United Nations programme designed to support environmentally and socially sustainable practices. Its efforts to sustainability were recognised last year with a Bronze award.

Contact

CEO
Email
Arndt Schottelius, MD. PhD, CEO
communications@maxion.co.uk
ICR Healthcare
Email
Mary-Jane Elliot / Ashley Tapp / Kate Hall
maxiontherapeutics@icrinc.com

About Maxion Therapeutics

Maxion Therapeutics is a biotechnology company developing antibody-based drugs for previously untreatable ion channel- and G protein-coupled receptor (GPCR)-driven diseases, including autoimmune conditions, chronic pain, and cardiovascular disease.

The Company is developing a pipeline of potentially first- and best-in-class therapeutics using its proprietary KnotBody® technology to generate potent, selective, and long-acting therapeutics by combining naturally occurring mini-proteins (‘knottins’) with antibodies using state-of-the-art phage and mammalian display technologies. Maxion was founded in 2020 by highly respected biotech entrepreneurs and scientists Dr John McCafferty, CTO and Dr Aneesh Karatt-Vellatt, CSO. Dr McCafferty previously co-invented antibody phage display, which was the subject of the 2018 Nobel Prize in Chemistry awarded to his co-inventor Sir Gregory Winter. Maxion’s portfolio and growth is being advanced by a team of highly experienced leaders in the discovery and development of antibody-based drugs. The Company is based near Cambridge, UK and is backed by international blue-chip investors.

For more information, please visit: https://www.maxiontherapeutics.com/

Contact

Discovering transformational therapies

admin@maxion.co.uk

Follow us on:
Address

The Works, Suite 4 — Unity Campus
London Road
Cambridge, CB22 3FT
United Kingdom